Bixiye
QP101-21 Commercial Pharmacy Benefit Update – Revised Drug-Related Prior Authorization (PA) Requirement Notification – Effective February 1, 2022
Taariikhda uu dhaqangalayo Barnaamijka: Des 08, 2021
Natiijooyinka Raadinta
Soo bandhiga 1961 - 1970 ee natiijooyinka 3688
Bixiye
Atopic Dermatitis (Elidel®, Eucrisa™, Protopic®, tacrolimus) - Commercial - Effective Date 02/01/2025
Step Therapy
Taariikhda uu dhaqangalayo Barnaamijka: 01, Feb 2025
Bixiye
Topical Antifungals - itraconazole, terbinafine - Medicaid
Prior Authorization, Quantity Limit
Taariikhda uu dhaqangalayo Barnaamijka: May 01, 2025
Bixiye
QP96-21 Processing Change for HCPCS Code A9279
Taariikhda uu dhaqangalayo Barnaamijka: Des 08, 2021
Bixiye
QP97-21 MHCP Pharmacy Benefit Exclusion for Asparlas™, Khapzory™, Nulojix®, Oncaspar® and Susvimo™
Taariikhda uu dhaqangalayo Barnaamijka: Des 08, 2021
Bixiye
QP98-21 Commercial Pharmacy Benefit Exclusion for Nulojix® and Susvimo™
Taariikhda uu dhaqangalayo Barnaamijka: Des 08, 2021
Bixiye
QP105-21 No-Cost Community Health Worker Services added to Commercial Plans
Taariikhda uu dhaqangalayo Barnaamijka: Des 22, 2021
Bixiye
QP106-21 Member Identification Cards Delayed
Taariikhda uu dhaqangalayo Barnaamijka: Des 22, 2021
Bixiye
Opioids Immediate Release (IR) New To Therapy with Daily Quantity Limit - Commercial
Quantity Limit
Taariikhda wax ku ool ah ee barnaamijka: Jun 01, 2025